Literature DB >> 34253193

Rheological effects of hypertonic saline and sodium bicarbonate solutions on cystic fibrosis sputum in vitro.

Mária Budai-Szűcs1, Szilvia Berkó2, Anita Kovács2, Pongsiri Jaikumpun3, Rita Ambrus2, Adrien Halász4, Piroska Szabó-Révész2, Erzsébet Csányi2, Ákos Zsembery3.   

Abstract

BACKGROUND: Cystic fibrosis (CF) is a life-threatening multiorgan genetic disease, particularly affecting the lungs, where recurrent infections are the main cause of reduced life expectancy. In CF, mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein impair transepithelial electrolyte and water transport, resulting in airway dehydration, and a thickening of the mucus associated with abnormal viscoelastic properties. Our aim was to develop a rheological method to assess the effects of hypertonic saline (NaCl) and NaHCO3 on CF sputum viscoelasticity in vitro, and to identify the critical steps in sample preparation and in the rheological measurements.
METHODS: Sputum samples were mixed with hypertonic salt solutions in vitro in a ratio of either 10:4 or 10:1. Distilled water was applied as a reference treatment. The rheological properties of sputum from CF patients, and the effects of these in vitro treatments, were studied with a rheometer at constant frequency and strain, followed by frequency sweep tests, where storage modulus (G'), loss modulus (G″) and loss factor were determined.
RESULTS: We identified three distinct categories of sputum: (i) highly elastic (G' > 100,000 Pa), (ii) elastic (100,000 Pa > G' > 1000 Pa), and (iii) viscoelastic (G' < 1000). At the higher additive ratio (10:4), all of the added solutions were found to significantly reduce the gel strength of the sputum, but the most pronounced changes were observed with NaHCO3 (p < 0.001). Samples with high elasticity exhibited the greatest changes while, for less elastic samples, a weakening of the gel structure was observed when they were treated with water or NaHCO3, but not with NaCl. For the viscoelastic samples, the additives did not cause significant changes in the parameters. When the lower additive ratio (10:1) was used, the mean values of the rheological parameters usually decreased, but the changes were not statistically significant.
CONCLUSION: Based on the rheological properties of the initial sputum samples, we can predict with some confidence the treatment efficacy of each of the alternative additives. The marked differences between the three categories suggest that it is advisable to evaluate each sample individually using a rheological approach such as that described here.
© 2021. The Author(s).

Entities:  

Keywords:  Bicarbonate; Cystic fibrosis; Hypertonic salt solutions; In vitro treatment; Rheology

Year:  2021        PMID: 34253193     DOI: 10.1186/s12890-021-01599-z

Source DB:  PubMed          Journal:  BMC Pulm Med        ISSN: 1471-2466            Impact factor:   3.317


  23 in total

1.  A superficial view of mucus and the cystic fibrosis defect.

Authors:  B K Rubin
Journal:  Pediatr Pulmonol       Date:  1992-05

2.  Hypertonic saline inhalation in cystic fibrosis--salt in the wound, or sweet success?

Authors:  Beth Enderby; Iolo Doull
Journal:  Arch Dis Child       Date:  2007-03       Impact factor: 3.791

Review 3.  Cystic fibrosis genetics: from molecular understanding to clinical application.

Authors:  Garry R Cutting
Journal:  Nat Rev Genet       Date:  2014-11-18       Impact factor: 53.242

4.  Safety, Tolerability, and Effects of Sodium Bicarbonate Inhalation in Cystic Fibrosis.

Authors:  Carla Cristina Souza Gomez; Paloma Lopes Francisco Parazzi; Karl Jan Clinckspoor; Renan Marrichi Mauch; Francisco Benedito Teixeira Pessine; Carlos Emilio Levy; Andressa Oliveira Peixoto; Maria Ângela Gonçalves Oliveira Ribeiro; Antônio Fernando Ribeiro; Douglas Conrad; Paul Marquis Quinton; Fernando Augusto Lima Marson; José Dirceu Ribeiro
Journal:  Clin Drug Investig       Date:  2020-02       Impact factor: 2.859

Review 5.  Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis.

Authors:  Christopher H Goss; Jane L Burns
Journal:  Thorax       Date:  2007-04       Impact factor: 9.139

Review 6.  Cystic fibrosis: impaired bicarbonate secretion and mucoviscidosis.

Authors:  Paul M Quinton
Journal:  Lancet       Date:  2008-08-02       Impact factor: 79.321

7.  Rheological Properties of Cystic Fibrosis Bronchial Secretion and in Vitro Drug Permeation Study: The Effect of Sodium Bicarbonate.

Authors:  Mariateresa Stigliani; Michele Dario Manniello; Olga Zegarra-Moran; Luis Galietta; Laura Minicucci; Rosaria Casciaro; Emilia Garofalo; Loredana Incarnato; Rita P Aquino; Pasquale Del Gaudio; Paola Russo
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-01-07       Impact factor: 2.849

8.  Normal mucus formation requires cAMP-dependent HCO3- secretion and Ca2+-mediated mucin exocytosis.

Authors:  Ning Yang; Mary Abigail S Garcia; Paul M Quinton
Journal:  J Physiol       Date:  2013-07-01       Impact factor: 5.182

9.  Hypertonic saline for cystic fibrosis: worth its salt?

Authors:  Jennifer L Goralski; Scott H Donaldson
Journal:  Expert Rev Respir Med       Date:  2014-03-26       Impact factor: 3.772

10.  Pathological mucus and impaired mucus clearance in cystic fibrosis patients result from increased concentration, not altered pH.

Authors:  David B Hill; Robert F Long; William J Kissner; Eyad Atieh; Ian C Garbarine; Matthew R Markovetz; Nicholas C Fontana; Matthew Christy; Mehdi Habibpour; Robert Tarran; M Gregory Forest; Richard C Boucher; Brian Button
Journal:  Eur Respir J       Date:  2018-12-06       Impact factor: 16.671

View more
  2 in total

Review 1.  Methods of Sputum and Mucus Assessment for Muco-Obstructive Lung Diseases in 2022: Time to "Unplug" from Our Daily Routine!

Authors:  Jeremy Charriot; Mathilde Volpato; Aurélie Petit; Isabelle Vachier; Arnaud Bourdin
Journal:  Cells       Date:  2022-02-25       Impact factor: 6.600

2.  Safety of chronic hypertonic bicarbonate inhalation in a cigarette smoke-induced airway irritation guinea pig model.

Authors:  Kata Csekő; Dóra Hargitai; Lilla Draskóczi; Adrienn Kéri; Pongsiri Jaikumpun; Beáta Kerémi; Zsuzsanna Helyes; Ákos Zsembery
Journal:  BMC Pulm Med       Date:  2022-04-07       Impact factor: 3.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.